Related Experiment Video
Updated: Sep 17, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9-Brief Report
Silvia Cecilia Pacheco-Velázquez1, Carlota Oleaga1, Bastian Ramms2
1Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland (S.C.P.-V., C.O., J.H., P.A.M., J.M., H.T., S.F., N.P.).
Background:
Hepatic heparan sulfate proteoglycans (HSPGs) accelerate the clearance of PCSK9 (proprotein convertase subtilisin/kexin type 9). We tested the hypothesis that free- and LDL (low-density lipoprotein)-bound PCSK9 forms have different HSPG-mediated clearance kinetics.
Methods:
Metabolic and turnover studies were performed after administration of free- and LDL-bound PCSK9 to 2 HSPG knockout mouse models: (1) Global knockout of syndecan-1 (Sdc1-/-), an HSPG involved in hepatic triglyceride clearance; and (2) hepatocyte-specific knockout of heparan sulfate N-deacetylase/N-sulfotransferase (AlbCre+Ndst1f/f).
Results:
The clearance of both free- and LDL-bound PCSK9 followed a 2-phase decay behavior comprising a fast and a slow phase. The more notorious effect of HSPG deletion was on the slow phase: the clearance of free-PCSK9 was faster in Sdc1-/- mice (t1/2,slow [half-life on the slow phase] 13.5±1.5 minutes; P=0.0305) than in wild-type (t1/2,slow 28.8±4.2 minutes) and AlbCre+Ndst1f/f mice (t1/2,slow 32.7±4.9 minutes). The clearance of LDL-bound PCSK9 was slower yet not statistically significant in Sdc1-/- mice (t1/2,slow 111.2±21.6 minutes) than in wild-type (t1/2,slow 52±6.4 minutes) and AlbCre+Ndst1f/f mice (t1/2,slow 39.55±2.96 minutes). However, the area under the curve showed a delayed clearance of LDL-bound PCSK9 in Sdc1-/- mice (44 576±2435 min×ng, P=0.004) but not in AlbCre+Ndst1f/f (34 738±3721 min×ng, P=0.578) mice compared with wild-type (30 865±1907 min×ng). Hepatic Ndst1-deficiency did not alter hepatic PCSK9 or LDLR (LDL receptor) expression.
Conclusions:
The clearance rate of plasma LDL-bound PCSK9 is slower than the clearance rate of its free form. The HSPG syndecan-1 modestly contributes to PCSK9 clearance through an LDLR-independent pathway.
More Related Videos
Related Concept Videos
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Elimination Kinetics: First-Order and Zero-Order
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is a drug's half-life, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...

